"We see exciting potential to develop new treatments for people with skin diseases through our strategic alliance with MorphoSys," said Gitte Aabo, CEO & President of LEO Pharma. "By joining forces to discover and develop new therapeutic antibodies, we aim to address a high unmet medical need among people with skin diseases. This partnership demonstrates our commitment to expanding our treatment offering and strengthening our position in biologics within dermatology."About MorphoSys: MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com. HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group. About LEO Pharma LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide. For more information, visit www.leo-pharma.com Subscribe to our YouTube channel: www.youtube.com/leopharmaglobal Follow us on Twitter: www.twitter.com/leohealthyskin Visit us at LinkedIn: www.linkedin.com/company/leo-pharma This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact: MorphoSys AG Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IRJochen Orlowski Associate Director Corporate Communications & IR Alexandra Goller Senior Manager Corporate Communications & IR Tel: +49 (0) 89 / 899 27-404 email@example.com LEO Pharma Eva Juul Langlands Media Relations Manager Tel: +45 4188 3094 firstname.lastname@example.org Media Release (PDF) http://hugin.info/130295/R/2052910/768373.pdf